Biopharma partners, Alnylam Pharmaceuticals and Genzyme, a subsidary of Sanofi, expand their long time collaboration by where Genzyme has invested $700 million in Alnylam.  Read the full story

KineMed biopharma partners with Amgen, a big pharma company, to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases Read the full story

Labcyte biopharma partners with AstraZeneca, a big pharma company, to use acoustic dispensing combined with mass spectrometry to greatly advance drug discovery applications Read the full story

GlaxoSmithKline , a big pharma company, announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services , for the provision of its inhalation anthrax treatment, raxibacumab, forming biopharma partners Read the full story

Sanofi, a big pharma company, and Genzyme biopharma partners  and announced a $1 million gift to support student success programs in the University of Massachusetts Boston’s College of Science and Mathematics Read the full story

Array BioPharma partners with Celgene Corporation for an Array-invented preclinical development program targeting a novel inflammation pathway Read the full story

Ambrx biopharma partners with Bristol-Myers Squibb, a big pharma company, for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology. Read the full story

Bristol-Myers Squibb, a big pharma company, biopharma partners with Quintiles, selecting the CRO giant to handle global central lab services for its pipeline treatments Read the full story

Vertex Pharmaceuticals, a big biotech company, biopharma partners in a non-exclusive agreement with Bristol-Myers Squibb , a big pharma company, to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex’s nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and Bristol-Myers Squibb’s NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C. Read the full story

Lundbeck and Otsuka , both amongst the top 50 big biotech companies, announced a license and development biopharma partners agreement Read the full story